CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
Hyperpolarized Helium-3 MRI of the chestdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02163681
NCT02163681N/ACompleted
CompareCT.gov

MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Young Children

University of Virginia·interventional·Posted Jun 16, 2014·Updated Apr 19, 2022

In Brief

A clinical study evaluating Hyperpolarized Helium-3 MRI of the chest for Healthy and 3 related conditions. Completed, enrolled 45 participants across 1 site.

Detailed Summary

The purpose of this study is to develop rapid MRI techniques for imaging the lung with hyperpolarized helium-3 gas as an inhaled contrast agent. These techniques will be piloted in adults and older children before testing them in younger children and infants. The purpose is to enable imaging of non-sedated infants by imaging so fast as to freeze motion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, Cystic Fibrosis (CF), Asthma, Bronchopulmonary Dysplasia (BPD)
CountriesUnited States
CollaboratorsXemed LLC

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 16, 2014
Enrollment StartJan 1, 2011
Primary CompletionJun 30, 2018
Study CompletionJul 30, 2018
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 12.0 years ago

Interventions

Hyperpolarized Helium-3 MRI of the chestdrug

hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.